NOVEL ASSAY METHODS FOR ETHYLENE GLYCOL TOXICITY

乙二醇毒性的新测定方法

• 批准号: 6014932
• 负责人: HANS G KLOEPFER
• 金额: $ 9.95万
• 依托单位: MICRONIX, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-01 至 2000-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6014932
• 关键词: blood chemistry; blood tests; blood toxicology; diagnosis design /evaluation; diagnostic tests; ethylene glycols; glycolates; method development; poisoning; prognosis; technology /technique development

DESCRIPTION: (Adapted from the applicant's abstract) Poisoning from ethylene glycol is a potentially lethal medical emergency but can be treated effectively when recognized early. Conversely when diagnosis is late, the outcome is usually poor. The major pathogenic factor is metabolic acidosis from glycolic acid (glycolate). Because laboratory testing for ethylene glycol and glycolate is severely restricted, timely diagnosis depends on comparatively nonspecific physical signs and laboratory tests. Lack of access to specific testing and need for differentiation from conditions featuring similar symptoms constitute a unique medical dilemma. Recognizing these deficiencies we propose to develop novel, specific enzymic assays for ethylene glycol and glycolate. Two product configurations are perceived: (1) aqueous reagents for existing clinical analyzers (serum, quantitative); (2) a dry-chemistry, dual-analyte point-of-care test strip method (whole blood, semi-quantitative). Because of rapid metabolism of (nontoxic) ethylene glycol and the longer half life of (toxic) glycolate, the latter provides: (1) better prognostic information; (2) improved clinical sensitivity, especially late post-ingestion. Thus, rapid and simultaneous availability of test results for both analytes expands the window of diagnostic/therapeutic opportunity. Socioeconomic benefits are: (1) reducing expensive gas chromatographic screening, confirmatory and other testing; (2) averting late or unnecessary treatment; (3) cutting intensive care and hospital stay; (4) abating long-term morbidity (renal dialysis). PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：（改编自申请人的摘要）乙烯中毒 乙二醇是一种潜在致命的医疗紧急情况，但可以有效治疗 当早期被识别时。相反，当诊断较晚时，结果是 通常很穷。主要致病因素是乙醇酸代谢性酸中毒 酸（乙醇酸盐）。因为乙二醇和乙醇酸酯的实验室测试 受到严重限制，及时诊断依赖于相对非特异性 体征和实验室测试。无法进行特定测试和 需要与具有相似症状的病症进行区分 一个独特的医疗困境。认识到这些缺陷，我们建议开发 乙二醇和乙醇酸酯的新颖、特异性酶测定法。两种产品 感知配置：（1）现有临床的水性试剂 分析仪（血清、定量）； (2) 干化学双分析物 即时检测试纸法（全血，半定量）。由于 （无毒）乙二醇的快速代谢和较长的半衰期 （有毒）乙醇酸盐，后者提供：（1）更好的预后信息； (2) 改善临床敏感性，尤其是摄入后晚期。因此，快速且 同时获得两种分析物的测试结果扩大了窗口 诊断/治疗机会。社会经济效益为：（1）减少 昂贵的气相色谱筛选、确证等测试； (2) 避免延迟或不必要的治疗； (3)削减重症监护室和医院 停留; (4) 减少长期发病率（肾透析）。 拟议的商业应用：不可用